Jin-feng Li

Dr. Jin-feng Li


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
HFHongzhao Fan
Hongzhao Fan
JLJia Liu
Jia Liu
JSJiajia Sun
Jiajia Sun
GFGuiwen Feng
Guiwen Feng
JLJin-feng Li
Jin-feng Li
Renal ischemia-reperfusion injury (IRI) is a non-negligible clinical challenge for clinicians in surgeries such as renal transplantation. Functional loss of renal tubular epithelial cell (TEC) in IRI leads to the development of acute kidney injury, delayed graft function (DGF), and allograft rejection. The available evidence indicates that cellular oxidative stress, cell death, microvascular dysfunction, and immune response play an important role in the pathogenesis of IRI. A variety of immune cells, including macrophages and T cells, are actively involved in the progression of IRI in the immune response. The role of B cells in IRI has been relatively less studied, but there is a growing body of evidence for the involvement of B cells, which involve in the development of IRI through innate immune responses, adaptive immune responses, and negative immune regulation. Therefore, therapies targeting B cells may be a potential direction to mitigate IRI. In this review, we summarize the current state of research on the role of B cells in IRI, explore the potential effects of different B cell subsets in the pathogenesis of IRI, and discuss possible targets of B cells for therapeutic aim in renal IRI.

20 May 2022 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
MYMiaoheng Yan
Miaoheng Yan
ZSZongmian Song
Zongmian Song
HKHongwei Kou
Hongwei Kou
GSGuowei Shang
Guowei Shang
CSChunfeng Shang
Chunfeng Shang
SCSongfeng Chen
Songfeng Chen
Low back pain (LBP) is quite common in clinical practice, which can lead to long-term bed rest or even disability. It is a worldwide health problem remains to be solved. LBP can be induced or exacerbated by abnormal structure and function of spinal tissue such as intervertebral disc (IVD), dorsal root ganglion (DRG) and muscle; IVD degeneration (IVDD) is considered as the most important among all the pathogenic factors. Inflammation, immune response, mechanical load, and hypoxia etc., can induce LBP by affecting the spinal tissue, among which inflammation and immune response are the key link. Inflammation and immune response play a double-edged sword role in LBP. As the main phagocytic cells in the body, macrophages are closely related to body homeostasis and various diseases. Recent studies have shown that macrophages are the only inflammatory cells that can penetrate the closed nucleus pulposus, expressed in various structures of the IVD, and the number is positively correlated with the degree of IVDD. Moreover, macrophages play a phagocytosis role or regulate the metabolism of DRG and muscle tissues through neuro-immune mechanism, while the imbalance of macrophages polarization will lead to more inflammatory factors to chemotaxis and aggregation, forming an “inflammatory waterfall” effect similar to “positive feedback,” which greatly aggravates LBP. Regulation of macrophages migration and polarization, inhibition of inflammation and continuous activation of immune response by molecular biological technology can markedly improve the inflammatory microenvironment, and thus effectively prevent and treat LBP. Studies on macrophages and LBP were mainly focused in the last 3–5 years, attracting more and more scholars’ attention. This paper summarizes the new research progress of macrophages in the pathogenesis and treatment of LBP, aiming to provide an important clinical prevention and treatment strategy for LBP.

28 January 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
YLYongsheng Luo
Yongsheng Luo
FLFeifei Luo
Feifei Luo
KZKuanxin Zhang
Kuanxin Zhang
SWShilei Wang
Shilei Wang
HZHaojie Zhang
Haojie Zhang
JLJin-feng Li
Jin-feng Li
Background: Antibody-mediated rejection (AMR) occupies a major position for chronic rejection after kidney transplantation. Regulatory B cell (Breg) has been reported to have an inhibitory immune function, which contributes to the resistance for AMR.Methods: A nested case–control study for nine healthy donors, 25 stable (ST) patients, and 18 AMR patients was performed to determine the type of Breg in maintaining immune tolerance and preventing AMR.Results: Compared to the ST group, circulating interleukin (IL)-10+ Bregs, but not Bregs, significantly decreased. The receiver operating characteristic (ROC) curve analysis revealed that rather than the circulating Bregs, decreased circulating IL-10+ Breg levels were positively associated with AMR. However, kidney B cell and IL-10 infiltration was significantly increased in the AMR group with high expression of C-X-C motif chemokine 13 (CXCL13). In addition, circulating IL-10+ Bregs, rather than Bregs, remained higher than those at pre-operation, during the 90-day post-operation in immune homeostasis.Conclusion: The circulating IL-10+ Breg levels are more appropriate measures for assessing the resistance of AMR after kidney transplantation.

1 October 2002 in Phosphorus, Sulfur, and Silicon and the Related Elements
Verified
Journal Article
Closed access
CYCheng-Ye Yuan
Cheng-Ye Yuan
KWKe Wang
Ke Wang
JLJin-feng Li
Jin-feng Li
ZLZu-Yi Li
Zu-Yi Li
Bioreduction of 3-substituted-2-oxoalkanephosphonates by baker's yeast afforded corresponding 2-hydroxy-alkanephosphonates in good yields and ee value. These compounds ( 2a,b ) could serve as useful chirons for the stereoselective synthesis of phosphorus analogs of (R)-Carnitine and (R)-GABOB.

29 August 2025 in Renal Failure
Verified
Journal Article
Open access
HWHuimeng Wang
Huimeng Wang
JSJiajia Sun
Jiajia Sun
YLYongsheng Luo
Yongsheng Luo
XLXiaohu Li
Xiaohu Li
JLJin-feng Li
Jin-feng Li
Ferroptosis represents a distinctive mechanism of cell death, differing from necroptosis, necrosis, and apoptosis. It is triggered by the accumulation of lipid peroxides, driven by iron-catalyzed reactions. This oxidative damage is essential for triggering the ferroptotic pathway. Compared with apoptosis and necroptosis, ferroptosis is activated earlier in acute kidney injury (AKI), serving as a preemptive mechanism of cell death. Ferroptosis acts as a link between synchronous waves of renal tubular cell death by triggering cell death amplification loops and connects cell damage with inflammatory responses, thus constituting a crucial stage in the progression of AKI. This paper discusses the mechanisms that trigger ferroptosis in AKI and how ferroptosis, as a preemptive mode of cell death, exacerbates AKI through ferroptotic waves, modulates inflammatory responses, triggering apoptosis, necroptosis, and pyroptosis.

28 March 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YLYin Liu
Yin Liu
YXYe Xu
Ye Xu
TOTao Ouyang
Tao Ouyang
JLJin-feng Li
Jin-feng Li
TWTianfeng Wang
Tianfeng Wang
YXYuntao Xie
Yuntao Xie
Our previous study suggested that the recurrent CHEK2 H371Y mutation is a novel pathogenic mutation that confers an increased risk of breast cancer. The purpose of this study was to investigate whether breast cancer patients with CHEK2 H371Y mutation were more likely to respond to neoadjuvant chemotherapy. We screened a cohort of 2334 Chinese women with operable primary breast cancer who received a neoadjuvant chemotherapy regimen for CHEK2 H371Y germline mutations. Pathologic complete response (pCR) was defined as the absence of tumor cells in the breast after the completion of neoadjuvant chemotherapy. Thirty-nine patients (1.7%) with CHEK2 H371Y germline mutation were identified in this cohort of 2334 patients. CHEK2 H371Y mutation carriers had a significantly higher pCR rate than non-carriers (33.3% versus 19.5%, P = 0.031) in the entire study population, and CHEK2 H371Y mutation-positive status remained an independent favorable predictor of pCR in a multivariate analysis (odds ratio [OR] = 3.01; 95% confidence interval [CI]: 1.34- 6.78, P = 0.008). CHEK2 H371Y carriers had a slightly worse distant recurrence-free survival than non-carriers (adjusted hazard ratio [HR] =1.24, 95% CI: 0.59-2.63). CHEK2 H371Y mutation carriers are more likely to respond to neoadjuvant chemotherapy than are non-carriers.